risedronic acid has been researched along with Sensitivity and Specificity in 7 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Six postmenopausal women with diagnosed osteopenia/osteoporosis received a single oral dose of 100 nCi 41Ca for skeleton labeling." | 2.73 | Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. ( Denk, E; Fattinger, K; Häuselmann, HJ; Hillegonds, D; Hurrell, RF; Kraenzlin, M; Vogel, J; Walczyk, T, 2007) |
| "This study was designed to develop a sensitive and rapid method for the quantitation of risedronate in human urine using ultra-performance liquid chromatography with ultra-violet detector (UPLC-UV) and to compare bioavailability parameter of 5, 35 and 150 mg risedronate." | 1.40 | UPLC-UV method for determination of risedronate in human urine. ( Chung, YH; Jeong, JH; Lim, CH; Seo, YH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seo, YH | 1 |
| Chung, YH | 1 |
| Lim, CH | 1 |
| Jeong, JH | 1 |
| Wasserfallen, JB | 1 |
| Krieg, MA | 1 |
| Greiner, RA | 1 |
| Lamy, O | 1 |
| Ghassabian, S | 1 |
| Wright, LA | 1 |
| Dejager, AD | 1 |
| Smith, MT | 1 |
| Thomson, AB | 1 |
| Appleman, S | 1 |
| Keelan, M | 1 |
| Wallace, JL | 1 |
| Vallano, PT | 1 |
| Shugarts, SB | 1 |
| Kline, WF | 1 |
| Woolf, EJ | 1 |
| Matuszewski, BK | 1 |
| Zhu, LS | 1 |
| Lapko, VN | 1 |
| Lee, JW | 1 |
| Basir, YJ | 1 |
| Kafonek, C | 1 |
| Olsen, R | 1 |
| Briscoe, C | 1 |
| Denk, E | 1 |
| Hillegonds, D | 1 |
| Hurrell, RF | 1 |
| Vogel, J | 1 |
| Fattinger, K | 1 |
| Häuselmann, HJ | 1 |
| Kraenzlin, M | 1 |
| Walczyk, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans[NCT02565602] | 10 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health[NCT01053481] | Early Phase 1 | 25 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for risedronic acid and Sensitivity and Specificity
| Article | Year |
|---|---|
Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Biopsy, Needle; Cytokines; Dinoprostone; Dose-R | 2003 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
5 other studies available for risedronic acid and Sensitivity and Specificity
| Article | Year |
|---|---|
UPLC-UV method for determination of risedronate in human urine.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Drug Stability; Etidronic Acid | 2014 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr | 2008 |
Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma.
Topics: Acetaminophen; Chromatography, High Pressure Liquid; Diazomethane; Drug Stability; Etidronic Acid; H | 2012 |
Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Etidronic Acid; Humans; Ions; Reference Standards; Reproducibi | 2003 |
A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.
Topics: Alendronate; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diazomethane; E | 2006 |